ixmyelocel-T

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ischemic Dilated Cardiomyopathy (IDCM)

Conditions

Ischemic Dilated Cardiomyopathy (IDCM)

Trial Timeline

Feb 20, 2013 → Mar 7, 2018

NCT ID

NCT01670981

About ixmyelocel-T

ixmyelocel-T is a phase 2 stage product being developed by Vericel for Ischemic Dilated Cardiomyopathy (IDCM). The current trial status is completed. This product is registered under clinical trial identifier NCT01670981. Target conditions include Ischemic Dilated Cardiomyopathy (IDCM).

What happened to similar drugs?

10 of 14 similar drugs in Ischemic Dilated Cardiomyopathy (IDCM) were approved

Approved (10) Terminated (3) Active (4)

✅RegadenosonAstellas PharmaApproved

✅StatinShionogiApproved

✅RepathaAmgenApproved

✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved

✅celecoxib + ibuprofen + placeboPfizerApproved

✅Eplerenone + Placebo or sugar pillPfizerApproved

🔄Milvexian + PlaceboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01670981	Phase 2	Completed	Feb 20, 2013	Mar 7, 2018	Ischemic Dilated Cardiomyopathy (IDCM)
NCT01483898	Phase 3	Completed	Feb 1, 2012	Mar 25, 2014	Critical Limb Ischemia
NCT01020968	Phase 2	Completed	Dec 1, 2009	Dec 5, 2013	Dilated Cardiomyopathy
NCT00765518	Phase 2	Completed	Sep 1, 2008	Sep 5, 2012	Dilated Cardiomyopathy
NCT00505219	Phase 3	Completed	Sep 1, 2007	Dec 1, 2010	Osteonecrosis

Competing Products

20 competing products in Ischemic Dilated Cardiomyopathy (IDCM)

See all competitors

Product	Company	Stage	Hype Score
Aspirin, Clopidogrel	Yuhan	Pre-clinical	26
DS-1040b + Placebo	Daiichi Sankyo	Phase 1/2	32
DS-1040b + Aspirin	Daiichi Sankyo	Phase 1	29
DS1040b + Placebo	Daiichi Sankyo	Pre-clinical	26
Pharmacological intensification based on olmesartan	Daiichi Sankyo	Phase 2	35
Regadenoson	Astellas Pharma	Phase 1	29
YM872 (zonampanel), t-PA (alteplase)	Astellas Pharma	Phase 2	35
Regadenoson	Astellas Pharma	Approved	43
ASP2246	Astellas Pharma	Phase 1/2	39
Gadolinium + Adenosine	Astellas Pharma	Phase 2/3	38
XY03-EA + XY03-EA Placebo	Sun Pharmaceutical	Phase 2	31
Redasemtide + Placebo	Shionogi	Phase 2	39
Statin	Shionogi	Approved	43
fospropofol + propofol	Eisai	Phase 2	35
PDE5 Inhibitors	Eli Lilly	Pre-clinical	26
SB623 Implant (2.5M) + SB623 Implant (5.0M)	Sumitomo Pharma	Phase 2	35
Mesenchymal stem cell + Placebo	Rohto Pharmaceutical	Phase 2	42
Elezanumab + Placebo	AbbVie	Phase 2	35
Balovaptan + Placebo	Roche	Phase 2	27
Repatha	Amgen	Approved	35